Press

Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023, at 8:30 A.M. ET

Feb 3 • 2 min read

Reunion Neuroscience Inc. (NASDAQ: REUN | TSX: REUN), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that the Company plans to release its business update and financial results for Reunion’s fiscal 2023 third quarter ended December 31, 2022, before market open on Tuesday, February 14, 2023….

PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX™ (Ketamine) in Parkinson’s Disease

Feb 3 • 5 min read

PharmaTher Holdings Ltd. (OTCQB: PHRRF | CSE: PHRM), a leader in advancing specialty ketamine pharmaceuticals, today submitted its meeting package with the U.S. Food and Drug Administration (“FDA”) to discuss advancing KETARX™ (racemic ketamine) into Phase 3 development as a treatment for levodopa-induced dyskinesia in Parkinson’s disease (“LID-PD”). This Type C meeting allows the Company…

Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue

Feb 3 • 3 min read

Small Pharma Inc. (TSXV: DMT | OTCQB: DMTTF), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces an update to its intellectual property (“IP”) portfolio. The Company has received a Notice of Allowance from the United States Patent and Trademark Office (the “USPTO”) for United States (“U.S.”) patent application no….

PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome

Feb 3 • 4 min read

PharmaTher Holdings Ltd. (OTCQB: PHRRF | CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce that it has applied with the U.S. Food and Drug Administration (“FDA”) to receive Orphan Drug Designation (“ODD”) for ketamine to treat Rett Syndrome, a rare genetic neurological disorder. Ketamine has been subject to a Phase 2…

Psyence and Eden Labs Announce Extraction and Product Development Collaboration

Feb 3 • 4 min read

Psyence Group Inc. (CSE: PSYG. | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that it has entered into a partnership with Eden Labs LLC, a product development and extraction technology company that has developed intellectual property and methodologies around the extraction…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441